Quantification tools for a novel tau PET marker in a rare neurological disease: 18F-PI-2620 in progressive supranuclear palsy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508718-40-00

Enrollment

Registered

2024-03-05

Start date

2025-01-09

Completion date

Unknown

Last updated

2024-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive supranuclear palsy, Parkinson's disease

Brief summary

PI-2620 uptake determined by standard uptake value ratio (SUVR)

Detailed description

SUVR of the base nuclei divided a reference region such as the brain stem., SUVR of the cerebral cortex divided into a reference region such as the brain stem., Association of PI-2620 uptake values with demographics, clinical variables and CSF biomarkers

Interventions

DRUG[18F]PI-2620

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PI-2620 uptake determined by standard uptake value ratio (SUVR)	—

Secondary

Measure	Time frame
SUVR of the base nuclei divided a reference region such as the brain stem., SUVR of the cerebral cortex divided into a reference region such as the brain stem., Association of PI-2620 uptake values with demographics, clinical variables and CSF biomarkers	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026